CN110267959B - 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物 - Google Patents

作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物 Download PDF

Info

Publication number
CN110267959B
CN110267959B CN201780076039.3A CN201780076039A CN110267959B CN 110267959 B CN110267959 B CN 110267959B CN 201780076039 A CN201780076039 A CN 201780076039A CN 110267959 B CN110267959 B CN 110267959B
Authority
CN
China
Prior art keywords
compound
chloro
phenyl
ethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780076039.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110267959A (zh
Inventor
李菁
赵海波
王志伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Priority to CN202210507333.8A priority Critical patent/CN114805366A/zh
Publication of CN110267959A publication Critical patent/CN110267959A/zh
Application granted granted Critical
Publication of CN110267959B publication Critical patent/CN110267959B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780076039.3A 2016-12-07 2017-12-07 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物 Expired - Fee Related CN110267959B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210507333.8A CN114805366A (zh) 2016-12-07 2017-12-07 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016108897 2016-12-07
CNPCT/CN2016/108897 2016-12-07
PCT/CN2017/114970 WO2018103688A1 (en) 2016-12-07 2017-12-07 IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210507333.8A Division CN114805366A (zh) 2016-12-07 2017-12-07 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物

Publications (2)

Publication Number Publication Date
CN110267959A CN110267959A (zh) 2019-09-20
CN110267959B true CN110267959B (zh) 2022-05-27

Family

ID=62491736

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780076039.3A Expired - Fee Related CN110267959B (zh) 2016-12-07 2017-12-07 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物
CN202210507333.8A Pending CN114805366A (zh) 2016-12-07 2017-12-07 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210507333.8A Pending CN114805366A (zh) 2016-12-07 2017-12-07 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物

Country Status (16)

Country Link
US (2) US11136323B2 (https=)
EP (1) EP3551630A4 (https=)
JP (2) JP7064495B2 (https=)
KR (1) KR20190091339A (https=)
CN (2) CN110267959B (https=)
AU (2) AU2017372377B2 (https=)
BR (1) BR112019011847A2 (https=)
CA (1) CA3045959A1 (https=)
EA (1) EA201991355A1 (https=)
IL (2) IL266986B (https=)
MX (1) MX394882B (https=)
NZ (1) NZ754944A (https=)
SG (1) SG10201912192RA (https=)
TW (2) TW202233190A (https=)
WO (1) WO2018103688A1 (https=)
ZA (1) ZA201903286B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202233190A (zh) * 2016-12-07 2022-09-01 英屬開曼群島商百濟神州有限公司 作為ＰＩ３Ｋδ抑制劑的咪唑並［１，５－Ａ］吡衍生物
TWI817956B (zh) 2017-09-08 2023-10-11 英屬開曼群島商百濟神州有限公司 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑
JP2023503230A (ja) * 2019-11-21 2023-01-27 ベイジーン リミテッド Ｐｉ３キナーゼデルタ阻害剤との組合せで抗ｏｘ４０抗体を用いる癌治療の方法
KR102344185B1 (ko) * 2020-02-26 2021-12-27 계명대학교 산학협력단 신규한 Pim 키나아제 억제제 및 이의 용도
JP2024521763A (ja) * 2021-05-27 2024-06-04 ベイジーン スウィッツァーランド ゲーエムベーハー Ｐｉ３ｋデルタ阻害剤の塩、その結晶形態、調製方法、及び使用
KR20240060647A (ko) * 2021-09-14 2024-05-08 베이진 엘티디 Btk 저해제와 pi3 키나제 저해제의 조합물을 이용하는 암 치료 방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1898240A (zh) * 2003-10-15 2007-01-17 Osi制药公司 咪唑并吡嗪类酪氨酸激酶抑制剂
CN102428087A (zh) * 2009-04-16 2012-04-25 西班牙国家癌症研究中心 用作激酶抑制剂的咪唑并吡嗪类化合物
WO2012107465A1 (en) * 2011-02-09 2012-08-16 F. Hoffmann-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
CN104066735A (zh) * 2012-01-10 2014-09-24 拜耳知识产权有限责任公司 作为akt激酶抑制剂的取代的咪唑并吡嗪
WO2015058084A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
CN105682658A (zh) * 2013-05-30 2016-06-15 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
MA40596B1 (fr) 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
TW202233190A (zh) * 2016-12-07 2022-09-01 英屬開曼群島商百濟神州有限公司 作為ＰＩ３Ｋδ抑制劑的咪唑並［１，５－Ａ］吡衍生物
TWI817956B (zh) 2017-09-08 2023-10-11 英屬開曼群島商百濟神州有限公司 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1898240A (zh) * 2003-10-15 2007-01-17 Osi制药公司 咪唑并吡嗪类酪氨酸激酶抑制剂
CN102428087A (zh) * 2009-04-16 2012-04-25 西班牙国家癌症研究中心 用作激酶抑制剂的咪唑并吡嗪类化合物
WO2012107465A1 (en) * 2011-02-09 2012-08-16 F. Hoffmann-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
CN104066735A (zh) * 2012-01-10 2014-09-24 拜耳知识产权有限责任公司 作为akt激酶抑制剂的取代的咪唑并吡嗪
CN105682658A (zh) * 2013-05-30 2016-06-15 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法
WO2015058084A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use

Also Published As

Publication number Publication date
US20220098202A1 (en) 2022-03-31
TW202233190A (zh) 2022-09-01
EA201991355A1 (ru) 2019-11-29
US20190367523A1 (en) 2019-12-05
TWI762534B (zh) 2022-05-01
EP3551630A4 (en) 2020-07-15
EP3551630A1 (en) 2019-10-16
AU2022203737A1 (en) 2022-06-23
CN114805366A (zh) 2022-07-29
IL290419B2 (en) 2023-02-01
US11136323B2 (en) 2021-10-05
KR20190091339A (ko) 2019-08-05
WO2018103688A1 (en) 2018-06-14
IL266986A (en) 2019-07-31
ZA201903286B (en) 2021-01-27
JP2022090051A (ja) 2022-06-16
CA3045959A1 (en) 2018-06-14
SG10201912192RA (en) 2020-02-27
BR112019011847A2 (pt) 2019-10-29
MX394882B (es) 2025-03-24
IL290419A (en) 2022-04-01
IL290419B (en) 2022-10-01
US11725012B2 (en) 2023-08-15
MX2019006612A (es) 2019-08-01
IL266986B (en) 2022-03-01
CN110267959A (zh) 2019-09-20
AU2017372377A1 (en) 2019-07-18
JP7064495B2 (ja) 2022-05-10
NZ754944A (en) 2023-02-24
AU2017372377B2 (en) 2022-03-03
JP2020500909A (ja) 2020-01-16
TW201833113A (zh) 2018-09-16

Similar Documents

Publication Publication Date Title
CN110267959B (zh) 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物
CN114787161B (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
KR101921486B1 (ko) ＰＡＲＰ억제제인 4Ｈ-피라졸로[1,5-ａ]벤즈이미다졸 화합물의 아날로그
CN102015705B (zh) 稠合的杂环衍生物及其用途
CN113166139A (zh) 作为HPK1抑制剂的吡咯并[2,3-b]吡啶及其用途
CN114341127A (zh) 作为hpk1抑制剂的氨基吡嗪化合物及其用途
CN120712252A (zh) 包含sos1抑制剂和抗癌药物的用于治疗癌症的药物组合物
CN120659784A (zh) 作为c-Kit激酶抑制剂的化合物和组合物
KR20220140710A (ko) 트리아졸로피리다진 유도체, 이의 제조 방법, 약물 조성물 및 용도
CN112313234B (zh) 作为a2a受体拮抗剂的吡唑并三唑并嘧啶衍生物
TWI817956B (zh) 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑
TW202438054A (zh) 作為ＭＴＡ－協同ＰＲＭＴ５抑制劑的５－胺基－６，８－二氫－１Ｈ－呋喃并［３，４－ｄ］吡咯并［３，２－ｂ］吡啶－２－甲醯胺衍生物
JP2020525469A (ja) 新規キノリノン化合物
HK40008309B (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
HK40008309A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
CN121311471A (zh) 异喹啉酮衍生物和4h-喹嗪酮衍生物以及其用于治疗疾病的药物组合物
HK40036174A (en) Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
EA040746B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kδ
HK40002986A (zh) 吡啶并嘧啶酮cdk2/4/6抑制剂
HK40012363A (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
HK1201265A1 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
HK1201265B (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
HK1241873B (zh) 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂-吡啶酮化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40008309

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220527